Dih Yih Chen
About Dih Yih Chen
Dih Yih Chen is the Associate Medical Director at BeiGene in San Mateo, California. He has extensive experience in clinical research and medical direction, having worked at various prominent pharmaceutical and medical companies.
Company
Dih Yih Chen is currently working at BeiGene as an Associate Medical Director in San Mateo, California. BeiGene is a biopharmaceutical company focused on developing innovative molecularly targeted and immuno-oncology drug candidates.
Title
Dih Yih Chen holds the title of Associate Medical Director. In this role, he is responsible for providing medical expertise and supporting clinical development and trials for oncology treatments.
Education and Expertise
Dih Yih Chen studied at Saint George's University, achieving an MD from 2004 to 2008. He completed his Masters of Science in Engineering in Bioengineering at the University of Pennsylvania from 1997 to 1998 and earned a Bachelor's of Science in Biomedical Engineering from Northwestern University from 1992 to 1996. His educational background provides a strong foundation in both medical and engineering disciplines.
Background
Dih Yih Chen has an extensive background in clinical research and development. His prior roles include Associate Medical Director and Clinical Scientist at Acerta Pharma B.V., Principal Clinical Research Scientist at Abbott, Clinical Research Associate II at St. Jude Medical, Research Associate III at Amgen, Research Associate at Baxter, and Resident Physician at Franklin Square Hospital Center. He has also gained research experience at Cedars-Sinai Medical Center, University of Pennsylvania School of Medicine, and various other institutions.
Achievements
Dih Yih Chen has presented results of a phase 2 clinical trial of zanubrutinib at the 2021 European Hematology Association Annual Meeting. He led investigator and clinical trial steering committee meetings and supported a phase 3 head-to-head clinical trial of zanubrutinib vs. ibrutinib in patients with Waldenstrom Macroglobulinemia. Additionally, he has supported meetings with key opinion leaders to evaluate the clinical development plan for zanubrutinib in B-cell malignancies.